Therapeutic Equivalency

"Therapeutic Equivalency" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.

Descriptor ID	D013810
MeSH Number(s)	G03.787.559 G07.690.725.898
Concept/Terms	Therapeutic Equivalency Therapeutic Equivalency Clinical Equivalencies Equivalencies, Clinical Equivalency, Clinical Generic Equivalency Equivalencies, Generic Equivalency, Generic Generic Equivalencies Equivalencies, Therapeutic Therapeutic Equivalencies Equivalency, Therapeutic Bioequivalence Bioequivalences Clinical Equivalency

Below are MeSH descriptors whose meaning is more general than "Therapeutic Equivalency".

Biological Sciences [G]
Metabolism [G03]
Pharmacokinetics [G03.787]
Therapeutic Equivalency [G03.787.559]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacokinetics [G07.690.725]
Therapeutic Equivalency [G07.690.725.898]

Below are MeSH descriptors whose meaning is related to "Therapeutic Equivalency".

Below are MeSH descriptors whose meaning is more specific than "Therapeutic Equivalency".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Therapeutic Equivalency" by people in this website by year, and whether "Therapeutic Equivalency" was a major or minor topic of these publications.

Bar chart showing 23 publications over 12 distinct years, with a maximum of 3 publications in 2000 and 2007 and 2009 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
2000	0	3	3
2001	0	2	2
2006	0	2	2
2007	1	2	3
2009	1	2	3
2010	1	1	2
2012	0	1	1
2014	0	1	1
2015	0	1	1
2016	0	1	1
2024	1	2	3

Below are the most recent publications written about "Therapeutic Equivalency" by people in Profiles.

Javidnia M, Irier HA, Kassim S, Cho SJ. Remote Regulatory Assessments of Bioavailability/Bioequivalence Study Conduct by the Office of Study Integrity and Surveillance. AAPS PharmSciTech. 2024 Oct 10; 25(7):240.

View in: PubMed
Zheng R, Lam E, Altshuler P, Crutcher M, Lavu H, Yeo CJ, Stickle D, Leiby B, Kraft WK. Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP). Int J Clin Pharmacol Ther. 2024 Jul; 62(7):319-325.

View in: PubMed
Falchook G, Patnaik A, Richardson DL, Harvey RD, Sharma MR, Hafez N, Hamilton E, Piha-Paul SA, Barve M, Wise-Draper T, Patel MR, Dowlati A, Pascuzzo J, Tang SC, Faltermeier C, Malinowska IA, Shtessel L, Striha A, Potocka E. A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. Clin Ther. 2024 03; 46(3):228-238.

View in: PubMed
Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Nov; 78(5):921-927.

View in: PubMed
Choudhry NK, Denberg TD, Qaseem A. Improving Adherence to Therapy and Clinical Outcomes While Containing Costs: Opportunities From the Greater Use of Generic Medications: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2016 Jan 05; 164(1):41-9.

View in: PubMed
Sharma S, Britten CD, Mortimer J, Kulkarni S, Quinlan M, Liu A, Scott JW, George D. The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Oct; 74(4):867-74.

View in: PubMed
Nair AK, Anand O, Chun N, Conner DP, Mehta MU, Nhu DT, Polli JE, Yu LX, Davit BM. Statistics on BCS classification of generic drug products approved between 2000 and 2011 in the USA. AAPS J. 2012 Dec; 14(4):664-6.

View in: PubMed
Blackstone EA, Fuhr JP. Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals. Future Med Chem. 2010 Nov; 2(11):1641-9.

View in: PubMed
Colon-Gonzalez F, Kraft WK. Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert Opin Drug Metab Toxicol. 2010 Oct; 6(10):1277-86.

View in: PubMed
Fuhr JP. Biosimilars and follow-on biologics. Expert Rev Pharmacoecon Outcomes Res. 2009 Apr; 9(2):149-50.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement